ORIGINAL ARTICLES

Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation
Søren Lund Kristensen, MD, PhD; Pardeep S. Jhund, MBChB, MSc, PhD; Ulrik M. Mogensen, MD, PhD; Rasmus Rørth, MD; William T. Abraham, MD; Akshay Desai, MD, MPH; Kenneth Dickstein, MD, PhD; Jean L. Rouleau, MD; Michael R. Zile, MD; Karl Swedberg, MD, PhD; Milton Packer, MD; Scott D. Solomon, MD; Lars Kober, MD, DMSc; John J.V. McMurray, MD; on behalf of the PARADIGM-HF and ATMOSPHERE Committees and Investigators

Editorial
Lessons Learned and to Be Learned About the Use of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure and Atrial Fibrillation
Adriaan A. Voors, MD, PhD; Carolyn S.P. Lam, MD, PhD

Early Right Ventricular Assist Device Use in Patients Undergoing Continuous-Flow Left Ventricular Assist Device Implantation: Incidence and Risk Factors From the Interagency Registry for Mechanically Assisted Circulatory Support
Michael S. Kiernan, MD, MS; E. Wilson Grandin, MD; Marshall Brinkley, Jr, MD; Navin K. Kapur, MD; Duc Thinh Pham, MD; Robin Ruthazer, MS; J. Eduardo Rame, MD; Pavan Atturi, MD; Edo Y. Birati, MD; Guilherme H. Oliveira, MD; Francis D. Pagani, MD, PhD; James K. Kirklin, MD; David Naftefl, MD; Robert L. Kormos, MD; Jeffrey J. Teuteberg, MD; David DeNofrio, MD

Precision Medicine for Cardiac Resynchronization: Predicting Quality of Life Benefits for Individual Patients—An Analysis From 5 Clinical Trials
Michael E. Nassif, MD, MSc; Yuanyuan Tang, PhD; John G. Cleland, MD; William T. Abraham, MD; Cecilia Linde, MD, PhD; Michael R. Gold, MD, PhD; James B. Young, MD; J. Claude Daubert, MD; Lou Sherfesee, PhD; Dan Schaber, PharmD; Anthony S.L. Tang, MD; Philip G. Jones, MS; Suzanne V. Arnold, MD, MHA; John A. Spertus, MD, MPH

Patient and Spousal Health and Outcomes in Heart Failure
Shannon M. Dunlay, MD, MS; Véronique L. Roger, MD, MPH; Susan A. Weston, MS; Lauren R. Bangerter, PhD; Jill M. Killian, BS; Joan M. Griffin, PhD

Dose-Dependent Effects of the Myosin Activator Omecamtiv Mecarbil on Cross-Bridge Behavior and Force Generation in Failing Human Myocardium
Ranganath Mamidi, PhD; Jiayang Li, BS; Kenneth S. Gresham, PhD; Sujeet Verma, PhD; Chang Yoon Doh; Arny Li, PhD; Sean Lal, PhD; Cristobal G. dos Remedios, DSc; Julian E. Stelzer, PhD

Activation of Autophagy Ameliorates Cardiomyopathy in Mybpc3-Targeted Knockin Mice
Sonia R. Singh, PhD; Antonia T.L. Zech, MSc; Birgit Geertz; Silke Reischmann-Düsener; Hanna Osinska, PhD; Maksymilian Prondzynski, MSc; Elisabeth Krämer; Qinghang Meng, PhD; Charles Redwood, PhD; Jolanda van der Velden, PhD; Jeffrey Robbins, PhD; Saskia Schlossarek, PhD; Lucie Carrier, PhD

ON MY MIND

Is the Way to Someone’s Heart Through Their Stomach? The Cardiorenal Paradox of Incretin-Based Hypoglycemic Drugs in Heart Failure
Milton Packer, MD
CORRESPONDENCE

Letter by Heinrich-Nols and Kreuzer Regarding Article, “Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients: A Randomized Controlled Pilot Trial”

Jutta Heinrich-Nols, MD; Jörg Kreuzer, MD

Response by Andreas et al to Letter Regarding Article, “Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients: A Randomized Controlled Pilot Trial”

Martin Andreas, MD, PhD; Roxana Moayedifar, MD; Georg Wieselthaler, MD; Michael Wolzt, MD; Julia Riebandt, MD; Thomas Habert, MD; Philipp Angleitner, MD; Thomas Schöglhofer, BSc; Dominik Wiedemann, MD; Heinrich Schima, PhD; Guenther Laufer, MD; Daniel Zimpfer, MD